Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | FPR1 | P21462 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | WRN | Q14191 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31713851 | 0.87 | PTGDR2 (0.42) | KDM4EAKR1B1MAPTFPR1FPR2 | |
| SCHEMBL31678760 | 0.83 | KDM4E (0.43) | KDM4EAKR1B1MAPTFPR1FPR2 | |
| SCHEMBL31664556 | 0.83 | AKR1B1 (0.45) | KDM4EAKR1B1MAPTFPR1FPR2 | |
| SCHEMBL31664583 | 0.83 | MAPT (0.41) | KDM4EAKR1B1MAPTFPR1FPR2 | |
| SCHEMBL31713788 | 0.81 | WRN (0.55) | KDM4EAKR1B1MAPTPTGDR2LMNA | |
| SCHEMBL31664555 | 0.81 | KDM4E (0.43) | KDM4EAKR1B1MAPTFPR1FPR2 | |
| SCHEMBL31713931 | 0.79 | MAPT (0.39) | KDM4EAKR1B1MAPTFPR1FPR2 | |
| SCHEMBL31387245 | 0.79 | WRN (0.41) | KDM4EAKR1B1MAPTLMNATRPA1 | |
| SCHEMBL31713857 | 0.78 | PTGDR2 (0.42) | KDM4EAKR1B1MAPTPTGDR2LMNA | |
| SCHEMBL31677885 | 0.77 | KDM4E (0.43) | KDM4EAKR1B1MAPTFPR1FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236622-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF WRN | INCYTE CORPORATION (US) | 2025-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236622-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF WRN | WRN, BLM, RECQL | KDM4E 3651/4885AKR1B1 2734/4885MAPT 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.